Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Skin Neoplasms represent a diverse group of malignant and pre-malignant lesions affecting the skin, ranging from basal cell carcinoma to advanced melanoma. Globally, incidence rates have been rising, with over 1.2 million new cases reported annually, highlighting a growing public health concern. The skin neoplasms pipeline analysis by Expert Market Research reveals robust development activity, with numerous immunotherapies, targeted agents, and combination treatments advancing through Early phase I to phase III trials, signaling a promising future for innovative treatment options.
-
Major companies involved in the skin neoplasms pipeline analysis include Boehringer Ingelheim, Guangzhou FineImmune Biotechnology Co., LTD., and others.
-
Leading drugs currently in the pipeline include BI 3810944 and others.
-
The skin neoplasms pipeline is gaining strong momentum as researchers unlock mutation-driven disease mechanisms and develop precision therapies for both common and rare cutaneous cancers. Growth is further propelled by tumor-agnostic biomarkers and next-generation intralesional or oncolytic approaches that enhance localized tumor control. Together, these advances are reshaping the future of skin cancer treatment.
Report Coverage
The Skin Neoplasms Pipeline Analysis Report by Expert Market Research gives comprehensive insights into skin neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for skin neoplasms. The skin neoplasms report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The skin neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with skin neoplasms treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to skin neoplasms.
Read more about this report - Request a Free Sample
Skin Neoplasms Pipeline Outlook
Skin neoplasms pipeline outlook reflects strong momentum in next‑generation therapies beyond traditional surgery, radiation, and chemotherapy, with immunotherapies and targeted agents transforming treatment paradigms.
Skin neoplasms treatment is significantly shaped by immuno-oncology advances, particularly the expanding role of checkpoint inhibitors in high-risk and advanced disease settings. PD-1 blockade continues to demonstrate durable benefit across selected skin cancer subtypes. A notable development occured in November 2025, the European Union approval of Libtayo (cemiplimab) as the first and only immunotherapy for adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation, based on compelling Phase 3 data showing significant reduction in recurrence risk, expanding options for earlier intervention in skin cancer management.
Skin Neoplasms Epidemiology
Skin neoplasms rank among the most common cancers worldwide, with a substantial global burden. In 2022, about 331,722 new cases of cutaneous melanoma were diagnosed, resulting in approximately 58,667 deaths. Non-melanoma skin neoplasms, primarily basal and squamous cell carcinomas, accounted for an estimated 1,234,533 new cases globally in the same year. Ultraviolet radiation-attributable cutaneous melanoma showed a higher incidence in males, who comprised 57% of cases (151,921 of 267,353), highlighting a gender disparity in UV-related skin cancer risk. These figures underscore the significant worldwide impact of skin cancer.
Skin Neoplasms – Pipeline Therapeutic Assessment
This section of the report covers the analysis of skin neoplasms drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The skin neoplasms pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Skin Neoplasms Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total skin neoplasms clinical trials. Phase I (31%), Phase II (48%), Phase III (16%) collectively highlighting a strong concentration of clinical activity in early- and mid-stage development. This distribution indicates a strong emphasis on mid‑stage development, particularly Phase 2 trials, reflecting a robust focus on efficacy evaluation and optimization before late‑stage approval. The pipeline outlook remains dynamic, with immunotherapies and targeted treatments leading innovation.
Skin Neoplasms Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the skin neoplasms pipeline analysis include small molecules, monoclonal antibodies, and peptides. The skin neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for skin neoplasms. For instance, in February 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Amtagvi (lifileucel), marking the first FDA‑approved cellular therapy for unresectable or metastatic melanoma in adults previously treated with standard therapies. This tumor‑infiltrating lymphocyte (TIL)‑based immunotherapy offers a novel option for patients with advanced melanoma that cannot be removed surgically or has spread, addressing a significant unmet need in solid tumor treatment.
Skin Neoplasms Clinical Trials – Key Players
The EMR report for the skin neoplasms pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides detailed skin neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Skin Neoplasms clinical trials:
- Boehringer Ingelheim
- Guangzhou FineImmune Biotechnology Co., LTD.
- Biocad
- Phio Pharmaceuticals Inc.
- Degron Therapeutics Co.
- Stella Pharma Corporation
- Vector Vitale LLC
- Merck Sharp & Dohme LLC
- GlaxoSmithKline
- Iovance Biotherapeutics, Inc.
Skin Neoplasms – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for skin neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of skin neoplasms drug candidates.
Drug: GSK2636771
GSK2636771 is an oral, selective PI3K-β inhibitor designed to target PI3K pathway-driven skin neoplasms, particularly those with PTEN loss. By blocking PI3K-β–mediated tumor proliferation and survival signaling, it aims to reduce malignant cell growth and enhance sensitivity to other targeted therapies. The drug is being developed by GlaxoSmithKline (GSK), a global leader in oncology innovation with an active pipeline in precision medicine and immuno-oncology. GSK continues to conduct clinical studies exploring its role across multiple solid tumors.
Drug: BI 3810944
BI 3810944 is an investigational small-molecule inhibitor from the apoptosis-modulating class, designed to disrupt prosurvival signaling pathways implicated in skin neoplasms. It promotes tumor cell death by blocking proteins that help malignant cells evade apoptosis. This mechanism makes it useful in treating difficult-to-target cutaneous tumors and resistant disease. The candidate is being developed by Boehringer Ingelheim, a research-driven pharmaceutical company known for advancing next-generation oncology platforms focused on targeted therapies and immunomodulation in solid tumors.
Drug: JMT108
JMT108 is an investigational drug candidate classified as a monoclonal antibody developed for oncology applications. It functions by selectively binding to a specific antigen expressed on tumor cells or within the tumor microenvironment, thereby interfering with pro-tumor signaling and enhancing anti-tumor immune responses. This targeted approach aims to improve cancer control while minimizing off-target effects. The candidate is being advanced by Conjupro Biotherapeutics, Inc., a clinical-stage biotech focused on innovative biologic therapies and next-generation antibody platforms for difficult-to-treat cancers.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Skin Neoplasms Pipeline Insight Report
- Which companies/institutions are leading the skin neoplasms drug development?
- Which company is leading the skin neoplasms pipeline development activities?
- What is the current skin neoplasms commercial assessment?
- What are the opportunities and challenges present in the skin neoplasms pipeline landscape?
- What is the efficacy and safety profile of skin neoplasms pipeline drugs?
- Which company is conducting major trials for skin neoplasms drugs?
- Which companies/institutions are involved in skin neoplasms collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in skin neoplasms?
Reasons To Buy This Report
The skin neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for skin neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into skin neoplasms collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Skin Neoplasms Epidemiology Forecast
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share